$145.61
+0.19%Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Executive Vice President & Chief Financial Officer
Compensation
$1,777,376
Executive Vice President & Chief People Officer
Compensation
$1,387,319
Executive Vice President & Chief Technology Officer
Executive Vice President & President of Interventional Segment
Compensation
$1,374,985
Executive Vice President & President of Medical segment
Compensation
$1,332,675
Executive Vice President of Technology & Global Services and Chief Information Officer
President, Chief Executive Officer & Chairman
Compensation
$3,733,112
Senior Vice President & Chief Scientific Officer
Senior Vice President, Chief Accounting Officer & Controller
Senior Vice President, Treasurer & Head of Investor Relations
During the last 12 months, insiders have purchased $1.01M and sold $923K worth of BDX shares, resulting in $82K of net buying activity.
0
0.00
224
34.06K
-34K
-$34K
0
0.00
2.4K
466.08K
-466K
-$466K
0
0.00
1.3K
245.86K
-246K
-$246K
5.3K
1.01M
921
177.42K
+828K
+$828K
Hayes Gregory
Director
$1.01M
Fraser Claire
Director
$338K
Garrison Michael David
Officer: Evp & Pres Med.Essntl&Biopharm
$249K
Scott Bertram L
Director
$212K
Feld Michael
Officer: Evp, Chief Revenue Officer
$124K
Moderately bullish with $82K net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
4 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
BDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | December 18, 2025 | December 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | December 19, 2024 | December 16, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | December 14, 2023 | December 14, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | December 15, 2022 | December 12, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | December 16, 2021 | December 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | December 17, 2020 | December 17, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | December 03, 2018 | January 22, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | December 14, 2017 | January 23, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | December 15, 2016 | January 24, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | December 17, 2015 | January 26, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.